BofA starts Bicara Therapeutics with a Buy on head and neck cancer potential

As previously reported, BofA analyst Tazeen Ahmad initiated coverage of Bicara Therapeutics (BCAX) with a Buy rating and $35 price target Bicara is developing ficerafusp alfa as “a potentially transformative drug” to treat head and neck cancer and initial Phase 1b data suggests it has potential for “clear differentiation” over the current standard of care, the analyst tells investors. Bicara is also exploring ficera in other tumor types and plans to present initial data in third-line and later colorectal cancer in the seceond, which “could provide initial validation,” the analyst added.